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INTRODUCTION 
 Gastric cancer was described in the early period of  1500 BC in 
manuscripts from ancient Egypt calledEbers Papyrus(1) . Gastric tumouris the 
fourth most common cancer and the second leading cause of  death due to 
cancer worldwide.(2).  
 Gastric cancer is more common in malethan in female in the ratio of 
2:1(1). It is a disease of elderlywith higher incidence around 65yrs. For last few 
years there is decline in incidence rate  in the western countries (4). In Asia it is 
still one ofthe most common malignancies accounting for 18% of all 
malignancies.In countries like Japan and Korea it accounts for 56% of 
malignancies (5). 
 Most of the gastric carcinoma cases are brought to attention at later stage 
making higher rate of poor prognosis. The histologicaland morphological  types 
of gastric carcinomas are  highly variable and may notcorrelate well with the 
prognosis of the patients.(15) 
 The  poor prognosis of  gastric adenocarcinoma is due to its late 
presentation, nonspecific symptoms like dyspepsia in early stage and limitations 
in treatment options. Molecular markers are vital in determining the disease 
progression and hence disease outcome, survival and prognosis.(15) An 
association between clinicopathologicalfeatures and molecular markers of 
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gastric adeno carcinomawould give a clue toward the relationship between them 
and hence provide usan extra tool to combat the high mortality due to these 
carcinomas(8). 
 HER-2/Neu receptor  also known as c-Erb-2, encodes a transmembrane 
tyrosine kinase receptor;which is similar to epidermal growth factor 
receptor.Protein encoded by this gene is  a growth factor receptor involved in 
growth and metastasis of malignant cells (10). 
       Though many studies  have been conducted in gastric carcinoma all over 
the world  for the expression of  HER-2/Neu and their prognostic significance, 
the results are still contradictory. Some found a statistically significant 
association of these markers with prognosis and survival, while others found no 
such association. 
 Targeted therapy toward HER-2/neucan be justifiedonly when sufficient 
data regarding the role of these moleculesin gastric adenocarcinoma is 
available. 
           The aim of this study  was to find the prevalence of  HER-2/neu 
expression in Gastric adeno carcinoma and to correlate it with various clinico-
pathologicalvariables 
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AIMS AND OBJECTIVES 
1. To study the various clinicopathological factors of 
gastricadenocarcinoma including age of incidence, sex predilection, 
location of tumour, clinical features, Endoscopic appearance, gross 
appearance and histologic grade.  
2. To determine the immunohistochemical expression of  HER-2/Neu in 
Gastric adenocarcinoma. 
3. To study the association of  HER-2/Neu in Gastric adeno carcinoma with 
known prognostic factors like age, sex, histological  grade and other 
variables like gross appearance and type of specimen received.  
4.  To study the prognostic significance of HER-2/Neu in Gastric carcinoma 
and its association with survival 
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REVIEW OF LITERATURE 
 Gastric adenocarcinoma is a malignant neoplasm arising from the 
glandular epithelial lining of stomach mucosa. The stomach is divided grossly 
into the following regions: cardia, fundus, corpus or body, (pyloric) antrum, 
and pylorus(9). The superomedial margin is termed the lesser curvature and the 
inferolateral margin is termed the greater curvature. The junction between the 
corpus and the antrum  on the serosal aspect ,in the lesser curvature is called as 
incisura. The mucosal folds  are called as rugae(9) 
 
 These anatomic regions show some correspondence to the three 
traditionally recognized microscopic types of gastric mucosa : cardiac , fundic 
and pyloric (antral) . All of these types of gastric gland are comprised of two 
major components foveola  and secretory portion. The foveolae represent the 
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most important area for the genesis of gastric carcinoma, in particular the layer 
of generative (stem) cells located at their base. 
Epidemiology: 
 The  incidence of gastric adenocarcinoma is increasingwith age and the  
peak incidence occurs at 60-80 years(1). Incidence of age  younger than 30 years 
are very rare. In India, the age range for stomach cancer is 35-55 years in the 
South and 45-55 years in the North. The disease shows a male preponderance in 
the ratio of 2:1 to 4:1.(5) 
 Gastric adenocarcinoma   develops  both in the proximal and the distal 
region. Incidence of distal gastric cancers is more in developing countries, 
blacks, and  lower socio-economic groups(7). Dietary factors and H. pylori 
infection are major risk factors for the development of distal tumors. Proximal 
tumors are more common in developed countries,  whites, and in higher socio-
economic classes(9). The  risk factors for proximal cancers are gastroesophageal 
reflux disorder and obesity.  Recently prevalence of proximal tumors in the rest 
of the world  is increased according to studies conducted. 
 The highest incidence  of gastric adenocarcinoa was noted in Eastern 
parts of Asia and Europe, and South America, while North America and Africa 
show the lowest recorded rates(8). Approximately 934,000 cases are detected 
each year . Japan and Korea have the highest gastric cancer rates in the world. 
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The Linxian province in China has  highest  incidence rate of  gastric cardia 
cancer in the world. 
 In India, southern and north-eastern states  has higher incidence of gastric 
carcinomawith Mizoram being highest.In view of  study conducted by the 
National Cancer Registry  in 2001, the number of new gastric adenocarcinoma 
cases were estimated to be approximately 35,675. The incidence rate of gastric 
adenocarcinomas  was four times higher in Southern India compared with 
Northern India. 
 The age-standardized incidence rates in Chennai were 13.6 per 100,000 
in male and 6.5 per 100,000 in female. The rates in rural population are lower 
than  the urbanpopulation. Early gastric cancer has a higher five year survival 
rate (up to95%) than those of advanced gastric cancer (10% -20%).A recent 
assessment of 556 400 deaths due to cancer in India in 2010 based on a 
nationally representative survey found that stomach cancer with a mortality rate 
of 12.6% is the second most common fatal cancer. 
Clinical features: 
 Gastric adenocarcinomas  have non-specific symptoms likeepigastric 
distress or pain,  vomiting or regurgitation, hematemesis, melena, 
anorexia,weight loss and fatigue(9). Early gastric cancers are usually 
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asymptomatic. Mostly proximal gastric cancer causes dysphagiaand distal 
gastric cancer causes gastric outlet obstruction. 
Etiopathogenesis: 
 Etiology of gastric cancer is multifactorial. The risk factors  associated are diet, 
lifestyle, genetic, socioeconomic status and other factors contribute to gastric 
carcinogenesis. 
Diet: 
Most consistent association with dietary factor is observed inintestinal type of 
gastric carcinoma. Fresh fruits and vegetables lower therisk due to the 
antioxidant actions of ascorbic acid, carotenoids, folates,tocopherols(9). Salt 
intake, smoked foods, pickled vegetables, chillipepper are found to be 
associated with high risk. 
Helicobacter pylori infection: 
 “H.Pylori is a Gram-negative microaerophilic, spiral bacterium seen in 
the mucosa of stomach  in those  with severe &chronic atrophic gastritis  .Many 
studies showed  evidence of strong association with 
H.Pyroliinfection.Gastricadenocarcinoma had anti H Pylori antibodies  in their 
serum stored 10  years before the diagnosis of cancer(9)” 
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“H. pylori causes  sequential progression of normal gastric epithelium into  
atrophic gastritis, intestinal metaplasia, and dysplasia to carcinoma. The 
bacterium produces  several products like urease  that cause gastric mucosal 
damage . H. pylori disrupts gastric barrier function via urease-mediated myosin 
II activation.The formation ofsevere gastritis with atrophy and intestinal 
metaplasia is correlated with infection by CagA-positive strains of the 
bacillus(9).” 
Hypochlorhydria: 
 Gastric carcinoma is associated with hypochlorhydria in 85–90% of the 
cases. Hypochlorhydriapromotes the growth of bacteria  which were thought to 
reduce dietary nitrate to nitrite and convert dietary amines  into carcinogenic N-
nitroso compounds(9). 
Molecular genetics: 
 “Allelic loss has been identified at a variety of loci on various 
chromosomes. The earliest molecular events appear to be methylation and 
silencing of genes such as P16, MLH1, MGMT, and Runx 3 . These events are 
not specific to the histologic subtypes of carcinoma, although a loss on 7q is 
associated with peritoneal metastases. Microsatellite instability is encountered 
in 10% to 44% of cases, and tends to occur more frequently in antral intestinal 
carcinomas that are characterized by low clinical stage, less frequent lymph 
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node metastases, and better clinical prognosis(10) . Gastric carcinoma is now 
regarded as a component of the Lynch syndrome (hereditary nonpolyposis 
colorectal cancer) . Germline E-cadherin mutations had been detected infamilies 
with hereditary diffuse gastric adenocarcinoma .” 
PRECURSOR LESIONS OF GASTRIC CANCER: 
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EARLY GASTRIC CANCER(17,18,19) 
 This term was first coined  in the Japanese literature to describe 
infiltrating adenocarcinomas in which the  growth is confined to the mucosa or 
submucosa of the stomach with or without lymph node metastasis. Early gastric 
adenocarcinoma is not the same as carcinoma in situ or gastric dysplasia 
conditions in which tumor cells have not penetrated the basement membrane 
and have no metastatic potential. Some cases of early gastric cancer may have 
isolated local lymph node metastases or even hepatic metastases, but most cases 
are still potentially curable by surgery. 
 A  subclassification of the gross appearances of early gastric cancer was 
devised by the Japanese Gastroenterological Endoscopic Society.(18) 
• Type I Exophytic lesion extending into the gastric lumen 
• Type II Superficial variant 
IIA  Elevated lesions with a height no more than the thickness of the adjacent 
mucosa 
IIB  Flat lesions 
IIC  Depressed lesions with an eroded but not deeply ulcerated appearance 
 Type III Excavated lesions that may extend into the muscularispropria 
without invasion . 
11 
 
 
 These terminologies correlates weakly with microscopic appearances and 
prognosis. Early gastric cancer is mainly identified in the distal stomach, 
particularly along the lesser curve . The incidence of multicentricity has been 
estimated at 10%(19). Most tumors are 2 cm or less in diameter, although cases 
as large as 8 cm have been described. The histology of early gastric cancer is 
similar to that of advanced cancer, with intestinal, diffuse, and mixed forms 
described. 
 For intramucosal tumour, the cure rate is  93% when no regional lymph 
node metastases are present, and 91% when they are present. For early cancers 
with submucosal involvement, the overall cure rate is 89%, which is 80% in 
cases with lymph node metastases . 
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Advanced Gastric adenocarcinoma: 
 When the tumour invades beyond submucosa of stomach wall, it is called 
as advanced gastric carcinoma. It implies that resection and cure of the tumour 
is difficult and does not indicate that the tumour is of higher stage. 
Dr.R.Borrman  classification ( Based on gross appearance)(9) 
Type I  –  Polypoid / Nodular 
Type II  –  Fungating 
Type III  –  Ulcerative 
Type IV  –  Diffusely infiltrative (linitisplastica) 
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Ulcers are common  in the antrum, on the  lesser curve. The ulcers are large 
with irregular margins, raised rolled out  edges, necrotic shaggy base. Fungating 
and nodular tumours are common in the body of the stomach  or fundus. 
Infiltrative tumours  spread superficially, producingplaque-like lesions that 
causes thickening of the entirestomach wall producing the so-called 
linitisplastica (leather bottle)stomach.Gelatinous appearance occurs in tumours 
producing mucin. 
 Several classifications based on the histological picture exist forgastric 
carcinoma. A few of the commonly used ones are the following 
Lauren’s classification: (1965)(23) 
                   Lauren divides gastric adenocarcinoma into two main types –  
                             1) Intestinal  
                             2) Diffuse.  
 Those with approximately equal portion of intestinal and diffuse 
components and those too undifferentiated   are called 
indeterminate/unclassified carcinomas. Of the 1344 tumours initially described 
by Lauren, 53% were intestinal type, 33% were diffuse type, and others were 
indeterminate/unclassified type.(23) 
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Intestinal carcinoma: 
 This type is common in males and older age group.They have a glandular 
pattern with tubules, papillary formation or solid components. The glands are of 
welldifferentiated to moderately differentiated grade. The  epithelium consists 
of pleomorphiccells with large hyperchromatic nuclei . The adjacent  mucosa 
often shows chronic gastritis, intestinal metaplasia or dysplasia.  
Diffuse carcinoma: 
 This type is common in younger age group and composed of dyscohesive 
and  diffusely infiltrating tumour cells with indistinct cytoplasm and   
hyperchromatic nuclei.  Desmoplasia is more pronounced and  there is no 
accompanying dysplasia or metaplasia.  
Mulligan and Rember  classification(1975) 
 Extends the Lauren classification with third type , pyloric gland 
carcinoma. They are commoner in men  than women. Histologically shows  
glands with tubular or papillary pattern containing cells showing vacuolation 
that stain well with PAS stain. 
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Ming’s Classification (1977)(25):  
           Ming classifies gastric tumour into 2 types  
                       Expanding type 
                       Infiltrating type 
Expanding type tumurs are with pushing margins  and  tumour nodules.   
 Infiltrative type  tumous are  ill defined with widely infiltrative tumour 
cells and collagenous stroma. It is more common under the age of 50. 
WHO Classification (2010(28)): 
 WHO classification of Gastric tumours is givenas follows, 
1) EPITHELIAL TUMOURS 
PRE MALIGNANT LESIONS 
Intraepithelial neoplasia (dysplasia) , low grade 
Intraepithelial neoplasia ( dysplasia) , high grade 
Adenoma 
CARCINOMA 
Adenocarcinoma 
           Papillary adenocarcinoma 
           Tubular adenocarcinoma 
           Mucinous adenocarcinoma 
           Poorly cohesive carcinoma ( including Signet-ring cell carcinoma) 
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 Adenosquamous carcinoma 
 Carcinoma with lymphoid stroma ( medullary carcinoma) 
 Hepatoid carcinoma 
 Squamous cell carcinoma 
 Small cell carcinoma 
 Undifferentiated carcinoma 
 Neuro endocrine  tumours (NET) 
   NET G1 ( carcinoid) 
  NET G2  
 Neuroendocrine Carcinoma (NEC) 
  Large cell NEC 
  Small cell NEC 
 Mixed adenoneuroendocrine carcinoma 
 EC cell serotonin producing NEC 
 Gastrin producing NET ( Gastrinoma) 
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2) MESENCHYMAL TUMOURS 
 Leiomyoma 
 PlexiformFibromyxoma 
 Granular cell tumour 
 Glomus tumour  
 Leiomyosarcoma 
 GI stromal tumour 
 Kaposi sarcoma 
 Synovial sarcoma 
3) LYMPHOMAS 
4) SECONDARY TUMOURS 
The Goseki Classification (1992) : 
 Based on the  degree of tubular differentiation and the amount of 
intracellular mucin present, 
Group I  -   well differentiated tubules & low intracellular mucin 
Group II  -   well differentiated tubules & plenty intracellular mucin 
Group III  -   poorly differentiated tubules & low  intracellular mucin 
Group IV  -   poorly differentiated tubules & plenty intracellular mucin 
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Carneiro Classification (1997) : 
1) Glandular, 
2) Isolated cell carcinomas,  
3) Solid variety  
4) mixed type 
Grading Of Gastric Carcinoma(9): 
1)Well differentiated:  
 shows well-formed glands, often resembling metaplastic intestinal 
epithelium. 
2)Moderately differentiated: 
intermediate between well differentiated andpoorly differentiated. 
3)Poorly differentiated:  
shows highly irregular glands that are recognized 
 with difficulty, or shows single cells that remain isolated or arranged in 
clusters with mucin secretions. 
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Spread and metastases (9) 
 Distal carcinomas of the stomach invade the duodenum and tumours of 
proximal stomach involve the esophagus. Serosal spread is common in  
infiltrative tumours  than  expanding types.Local extension  occurs in omentum, 
colon, pancreas, and spleen. The rich mucosal and submucosal (Borrman) 
lymphatic plexus of the stomach is often invaded and cause the tumor to spread 
to perigastric, periaortic, and celiac axis nodes.Tumors of the distal third often 
involve  hepatoduodenal nodes. Mucosal lymphangiectasia is  found to be 
statistically associated with the presence of regional lymph node metastases. 
Invasion of the blood vessel walls by the tumor (‘vasculitiscarcinomatosa’) can 
also occur. 
 The most frequent sites of distant metastases are , peritoneum, liver, 
adrenal gland, lung  and ovary. Bilateral ovarian metastases from gastric 
carcinoma is known as Krukenbergtumor. Metastases can also develop in the 
uterine body and cervix. Cutaneous metastases of gastric carcinoma can be 
produced by gastric tumours. 
 The diffuse type of gastric carcinoma shows more frequent involvement 
of peritoneum, lungs, and ovary.Liver metastases are more common with 
intestinal-type tumors. 
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STAGING OF GASTRIC TUMOURS(10) 
TNM Staging of Gastric Carcinoma 
Tis  Carcinoma in situ 
T1a  Tumor invades lamina propria 
T1b  Tumor invades submucosa 
T2a  Tumor invades muscularispropria 
T2b  Tumor invades subserosa 
T3  Tumor penetrates visceral peritoneum 
T4  Tumor invades adjacent structures 
N0  No regional nodes involved 
N1  Tumor involves 1-6 regional nodes 
N2  Tumor involves 7-15 regional nodes 
N3  Tumor involves more than 15 regional nodes 
M0  No distant metastases 
M1  Distant metastases present 
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PROGNOSIS: 
“The prognosis of gastric carcinoma varies from country to country.The overall 
survival rate in the Western countries is 4 to 13% which is poor compared to 
Japan which shows the best results with an overall 5-year survival rate of 89% 
for early carcinoma and 46% for advanced carcinoma. This is atleast partly by 
the greater frequency of superficial carcinomas, and aggressive Japanese 
surgical approach to treatment with extensive and meticulous lymph node 
dissection.” 
PROGNOSTIC FACTORS(9): 
Prognostic factors includeclinical factors, morphological factors and/or genetic / 
molecular factors. 
            The clinical factors which indicate poor prognosis are young age and 
proximal location of gastric cancers(24). Some of the important Pathologic 
factors are as follows, 
1.  Tumour size: Small size is associated with a better prognosis but this 
isclosely linked to depth of penetration. 
2.  Tumour stage: This is the most significant prognostic factor. Depth of 
invasion is considered in staging which is directly proportional to the 
chance of distant metastasis. 
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3.  Microscopic type and grading: Intestinal type tumours has relatively 
better prognosis than diffuse types. 
4.  Lymphocytic response: Presence of inflammatory infiltrate at tumour and 
normal tissue interface is associated with good patient survival. 
5.  Lymphovascular invasion: Indicates infiltration of tumour cells into 
vascular spaces increasing the risk of recurrence and distant 
metastasis.Hence associated with poor prognosis. 
6.  Perineural invasion: It is associated with  poor prognosis. 
7.  Regional lymph node involvement: When nodal involvement is present, 
5 Year survival rate drops to below 10% and it is 50% in the node 
negative cases. The number of nodes involved is also significant. 
Overallsurvival rate decreases as the number of positive node increases. 
 Other factors found to have poor prognosis are tumour necrosis, 
infiltrative margins of tumour and involvement of surgical margins 
 Molecular biomarkers play an important  prognostic role in gastric 
carcinoma management. These markers are HER -2 , E- Cadherin , P-53. 
Aneuploidy has been reported in about 40–50% of gastric carcinomas  and 
show lower survival rates compared to diploidcancers. Over expression of 
HER-2/Neu which is a transmembraneepidermal growth factor receptor protein 
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is reported to have poorer prognosis, but some other  studies showed no such 
association. p53 protein over expression is associated with decreased survival. 
E-cadherin, a transmembrane protein plays a significant role in maintenance of 
intercellular connections. Mutations in Ecadherin gene is associated with 
aggressive behaviour..  Increased proliferation indices like Ki-67 are shown to 
be associated with reduced survival. 
HER2 protein and gene  
 “The human epidermal growth factor receptor family of receptors plays a 
central role in the pathogenesis and treatment of several human cancers(11). They 
regulate cell growth, survival, and differentiation by way of multiple signal 
transduction pathways and play a role in cellular proliferation and 
differentiation.  HER1 (EGFR), HER2, HER3 (ErbB-3), and HER4 (ErbB-4) 
are four members of this gene family.All four HER receptors comprise a 
cysteine-rich extracellular ligand binding site and intracellular domain with 
tyrosine kinase activity.” 
 The Her -2 / neu oncogene  was found by scientists at Massachusetts 
Institute of Technology, Rockefeller, and Harvard University .The binding of 
various ligands to the extracellular domain causes a signal transduction cascade 
that can control cell proliferation, apoptosis,  differentiation.adhesion, and 
migration. 
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“The HER2 receptor is a 1255 amino acid, 185 kDtransmembrane glycoprotein 
located at the long arm of human chromosome 17 (17q12) . HER2 is expressed 
in many tissues including the breast,Kidney, gastrointestinal tract, heart and its 
major use is to facilitate excessive/uncontrolled cell growth and tumorigenesis 
.” 
 
                                   Signal Transduction by the HER Family 
 There are receptor-specific ligands for HER1, HER3, and HER4. An 
intracellular tyrosine kinase domain exists for HER1, HER2, and 
HER4.Phosphorylation of the tyrosine kinase domain by means of dimerization  
causes  cell proliferation and survival signaling. HER2 is the preferred 
dimerization partner for the other HER family members. 
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“The phosphorylated (activated) tyrosine residues on the intracellular domain of 
HER2 activate the lipid kinase phosphoinositide 3-kinase (PI3-K), which 
phosphorylates a phosphatidylinositol that in turn binds and phosphorylates the 
enzyme Ak transforming factor (Akt), driving cell survival. One of many other 
downstream effects is the production of vascular endothelial growth factor 
(VEGF) supporting angiogenesis[11]“ 
 In carcinomas, HER2 acts as an oncogene, mainly because high-level 
amplification of the gene induces protein overexpression in the cellular 
membrane and subsequent acquisition of advantageous properties for a 
malignant cell . 
HER2 protein overexpression in gastric cancer (11) 
  Overexpression of HER2 in gastric cancer is very much  correlated with 
bad prognosis. It is also correlated with increased risk of local growth and 
distant metastasis(11).  Prevalence Studies on HER2 positivity  with gastric 
cancer revealed the frequency of HER2-positive gastric cancer ranging from 6.0 
to 36.6 % . Studies, which determines HER2 overexpression by IHC using 
monoclonal antibody  and/or gene amplification by FISH found similar results. 
 HER2 overexpression was found in 23% cases by IHC study  and  27%  
cases by gene amplification (FISH) in a study of 200 specimen conducted by 
Yano et al(51). Gravalos and Jimeno found that HER2 overexpression is  most 
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commonly found in gastroesophageal junction (GEJ) tumors and tumors  with  
intestinal type histology . Various studies also showed a higher rate of HER2 
over expression in GEJ tumors and intestinal subtype .  HER2 as a prognostic 
factor in gastric cancer is controversial because some initial studies failed to 
find an association with prognosis.  
 Some studies showed  that  HER2  over expression was correlated with 
worse prognosis, while others found no association between the two. In a study  
involving 260 gastric cancers, HER2 positivity  was an independent negative 
prognostic factor and HER2 staining intensity was correlated with tumor size, 
serosal invasion, and lymph node metastases . Another retrospective study  
involving 108 cases, HER2 overexpression was associated with a poorer 10-
year survival(11).  
 HER2 positivity is considered as the second poorest prognostic variable 
in early gastric carcinoma according to Nakajima et al(13) 
 “Intestinal-type gastric cancers showed higher rates of HER2 
overexpression  than the  diffuse-type cancers (P<0.05). Tumors with HER2 
amplification are correlated with poor mean survival rates (922 vs 3243 days) 
and 5-year survival rates (21% vs 63%;P< 0.05). Age, TNM stage, and 
amplification of HER2 were found to be independently related to survival by 
multivariate analysis.” 
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 Immunohistochemically, a positive reaction is considered in the presence 
of brown transmembrane staining and the scoringsystem to identify HER-2/Neu 
over expression is as follows, 
 
Immunohistochemistry(11) 
 Albert Coons et al in 1941 first labelled antibodies directly with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, introducedindirect 
labelling technique in which unlabelled antibody is followed bysecond antibody 
or substrate. Various stages of development ofImmunohistochemistry include 
peroxidase – antiperoxidase method(1970), alkaline phosphatase labelling 
(1971), avidin biotin method(1977) and two layer dextrin polymer technique 
(1993). 
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Antigen Retrieval: 
 Antigen retrieval can be done by the following different techniques  to 
unmask the antigenic determinants of fixed tissue sections. 
1.  Proteolytic enzyme digestion 
2.  Microwave antigen retrieval 
3.  Pressure cooker antigen retrieval 
4.  Microwave and trypsin antigen retrieval 
Proteolytic Enzyme Digestion: 
 Huank et al in 1976 introduced this technique to breakdown   formalin 
cross linkages and to unmask the antigen determinants. The most commonly 
used enzymes include trypsin and proteinase. The disadvantages include over 
digestion, under digestion and antigen destruction. 
Microwave Antigen Retrieval: 
 This is a new technique most commonly used in current 
practice.Microwave oven heating involves boiling formalin fixed paraffin 
sectionsin various buffers for rapid and uniform heating . 
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Pressure Cooker Antigen Retrieval(51) 
 Miller et al in 1995 compared and proved that pressure cookingmethod 
has fewer inconsistencies, less time consuming and can be used toretrieve large 
number of slides than in microwave method. 
Pitfalls of Heat Pre-treatment: 
 Drying of sections at any stage after heat pre-treatment 
destroysantigenicity. Nuclear details are damaged in poorly fixed tissues. 
Fibersand fatty tissues tend to detach from slides while heating. Not all 
antigensare retrieved by heat pre-treatment and also some antigens like PGP 
9.5show altered staining pattern. 
Detection Systems: 
 After addition of specific antibodies to the antigens, next step is 
tovisualize the antigen antibody reaction complex. The methods employedare 
direct and indirect methods. In the direct method, primary antibody isdirectly 
conjugated with the label. Most commonly used labels areflourochrome, horse 
radish peroxidase and alkaline phosphatase.  
 Indirect method is a two-step method in which labelled secondary 
antibody reactswith primary antibody bound to specific antigen. The use of 
peroxidise enzyme complex or avidin biotin complex further increases the 
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sensitivityof immunohistochemical stains. In 1993, Pluzek et al 
introducedenhanced polymer one step staining, in which large numbers of 
primaryantibody and peroxidase enzymes are attached to dextran polymer 
backbone. This is the rapid and sensitive method. Dextran polymerconjugate 
two step visualization system is based on dextran technology inEpos system. 
This method has greater sensitivity and is less timeconsuming. 
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MATERIALS AND METHODS 
 This study is a retrospective study of gastric carcinoma conducted in the 
Department of Pathology, Government Kilpauk Medical College, Chennai 
during the period of  July 2014 to June 2016. Endoscopic biopsy from stomach 
as well as resected specimens (subtotal, total, radical and palliative 
gastrectomy) from the Departmentof Surgery and  Surgical Gastroenterology , 
Govt. Kilpauk Medical college Hospital, which  were received in Department of 
Pathology, Govt. Kilpauk  Medical College  and reported as adenocarcinoma 
were included for the study. 
 Study population: Patients diagnosed as having gastric adenocarcinoma 
by Histopathological examination. 
Inclusion Criteria: 
Histopathologically proven cases of  Gastric adenocarcinomas. 
Exclusion Criteria: 
                  Patients diagnosed with gastric neoplasms other than gastric 
adenocarcinoma like, 
                   -  Gastric lymphomas 
                   -  Neuroendocrine tumours 
                   -  Mesenchymal neoplasms 
                   -  Poorly differentiated tumours 
                   -  Metastatic tumours 
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Data collection and Methodology: 
           Data of Gastric adenocarcinoma patients will be collected from the 
registers and case records . 
 Retrospectively patient’s tissue blocks will be analysed by 
immunohistochemical study for the expression of Human Epidermal Growh 
Factor Receptor -2 and graded appropriately. 
Variables studied 
 The following clinical and pathological parameters were evaluated. Age, 
gender,  location (cardia, body, pyroloantrum, fundus), gross appearance 
(ulcerative, nodular, ulceroproliferative, diffuse),endoscopic appearance 
,histological grade (well differentiated, moderately differentiated,poorly 
differentiated) and Her -2 receptor expression. 
Immunohistochemical evaluation 
 Immunohistochemical analysis was done in paraffin embedded tissue 
samples using supersensitive polymer HRP system based on nonbiotin 
polymeric technology. 4 micron thick sections from formalin fixed paraffin 
embedded tissue samples were transferred onto gelatin coated slides. Heat 
induced antigen retrieval was done. The antigen was bound with mouse 
monoclonal antibody  HER-2/Neu proteins and then detected by the addition of 
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secondary antibody conjugated with horse radish peroxidase polymer and 
diaminobenzidine substrate. 
 The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization, percentage of cells stained and 
intensity of staining. Cytoplasmic membrane staining was assessed for HER-
2/Neu  positivity. 
Data entry 
 All the data collected and the results obtained were entered into Excel 
2007. 
Statistical analysis 
 The collected data were analysed with IBM.SPSS statistics software 23.0 
Version.To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean & S.D 
were used for continuous variables. To find the significant difference between 
the bivariate samples in Independent groups the Unpaired sample t-test was 
used. To find the significance in categorical data Chi-Square test was used. In 
both the above statistical tools the probability value(P value) .05 is considered 
as significant level.  
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AGE DISTRIBUTION 
 Regarding age distribution, the mean age of incidence is 60.3yrs, the 
youngest age being 27 yrs and oldest age being 80 yrs. The percentage of 
people under 50 yrs of age is 23%(23 cases) and above or equal to 50 is 77% ( 
77Cases). (Table .2 and Chart 2) 
Age No.of cases Percentile 
< 50 yrs 23 23% 
>50 yrs 77 77% 
Table.2 – Age distribution in study population 
SITE DISTRIBUTION 
               In the study population , most of the gastric carcinomas were located 
at pyloro- antral region , the percentage being 60%,      least cases occurred in 
cardia with 6%.( Table .3 and Chart 3) 
Table.3- Site wise distribution Gastric cancer 
SITE Percentage of incidence 
Cardia 6% 
Body 27% 
Fundus 7% 
Pyloro - antrum 60% 
TOTAL 100% 
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Chart.2 – Age distribution in study population 
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CLINICAL SYMPTOMS 
 Among the presenting complaints of the patients, abdominal pain(only) 
tops the list with 29% and the least being only loss of weight and apetite – 5%( 
Table. 4 and Chart .4) 
Table .4 – Clinical features of study population 
Clinical Features Percentage % 
Abdominal pain 29 
Obstruction 7 
Loss of Weight &Apetite 5 
Abdominal pain  & Loss of Weight  and 
Apetite 
22 
Abominal pain & obstruction 21 
Obstruction & Loss of Weight&Apetite 5 
All the three 11 
TOTAL 100 
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Endoscopic appearance 
                 Most of cases are reported as Ulcers (73%). Remaining 23% cases 
were reported as growth .( Table5 &Chart5) 
Table -5 showing endoscopic appearance of study population 
Endoscopic appearance Frequency Percent 
Ulcer 73 73.0 
Growth 27 27.0 
Total 100 100.0 
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GROSS APPEARANCE: 
                In my study population, the common gross pattern is proliferative 
(50%), the next being ulcerative (45%) and the least one is Polypoidal (2%). 
(Table.6 and Chart,6) 
Table 6 Showing gross appearance distribution 
Gross appearance Frequency Percent 
Ulcerative 45 45.0 
Proliferative 50 50.0 
Polypoidal 2 2.0 
Infiltrative 3 3.0 
Total 100 100.0 
 
HISTOLOGIC GRADE: 
          In the study population, most of the cases are moderately 
differentiated(42%). Poorly differentiated tumours accounts for 41% and 17 % 
cases were well differentiated.(Table .7 and Chart .7) 
Histologic Grade Frequency Percent 
Well differentiated 17 17.0 
Moderately differentiated 42 42.0 
Poorly differentiated 41 41.0 
Total 100 100.0 
 
Table .7 Distribution of different histological grade 
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HER -2 / NEU RECEPTOR EXPRESSION: 
25% of cases were positive for Her-2 receptor. Moderately differentiated(52%) 
and well differentiated(28%) tumours shows more positivity than poorly 
differentiated tumours(20%). ( Table.8 & Chart.8) 
Table -8 Expression of Her -2 receptor in study population 
Her – 2 Status Frequency Percent 
Positive 25 25.0 
Negative 75 75.0 
Total 100 100.0 
 
 In the study population , 73 cases were endoscopic biopsies and 27 are 
gastrectomy specimen.(Table.9 and chart 9).In endoscopic biopsies, 54 cases 
are male and 20 were female.amonggastrectomy specimen, 15 cases are male 
and 11 were female. 
Table -9 Type of specimen obtained in study population 
Small 73 73.0 
Gastrectomy 27 27.0 
Total 100 100.0 
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Figure 5: Poorly differentiated grade with cells arranged in sheets and filled 
with mucin        10x, H &E 
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Figure 5.HER-2/Neu Score 3+, 
Strong intense completemembranous staining in alltumour cells, 40x, 
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Figure 6- HER-2/Neu Score 2+, 
Moderate intense complete staining in  > 10% of tumour cells 
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Figure 7 : HER-2/Neu Score 1+, 
Incomplete membranous staining in < 10 % of tumour cells,40x 
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Correlation of HER -2 with Various Clinicopathological Factors: 
Table 10: Association of age of patient with HER -2 expression 
HER - 2 
Total Positive Negative 
Agerange < 50 yrs Count 6 17 23 
  % within HER - 2 24.0% 22.7% 23.0% 
>=50 yrs Count 19 58 77 
  % within HER - 2 76.0% 77.3% 77.0% 
Total Count 25 75 100 
% within HER - 2 100.0% 100.0% 100.0% 
 
Chi Squre test :P Value -0.891( > 0.05) 
 The percentage of  patients with age < 50 yrs showing HER-2/Neu over 
expression is 26.1% and in those with age  more than 50 yrs, overexpression of 
Her -2 seen in 25 %. There was no significant difference in the age at 
presentation between the two groups (Table 10 & Chart 10) 
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Table 11: Association of Gender with HER-2/Neu Expression 
  
HER - 2 
Total Positive Negative 
GENDER Male Count 15 53 68 
  % within HER - 2 60.0% 70.7% 68.0% 
Female Count 10 22 32 
  % within HER - 2 40.0% 29.3% 32.0% 
Total Count 25 75 100 
% within HER - 2 100.0% 100.0% 100.0% 
 
Chi square test :P value - 0.322 ( >0.05) 
Of the cases showing HER-2/Neu over expression, 60% were 
males and 40% were females and there was no significant difference in 
sex wise distribution. (Table 11 & Chart 11) 
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Table 12: Association of Site with HER-2/Neu Expression 
  
HER - 2 
Total Positive Negative 
SITE Cadria Count 1 5 6 
% within HER - 2 4.0% 6.7% 6.0% 
Body Count 4 23 27 
% within HER - 2 16.0% 30.7% 27.0% 
Fundus Count 1 6 7 
% within HER - 2 4.0% 8.0% 7.0% 
PuloroAntrum Count 19 41 60 
% within HER - 2 76.0% 54.7% 60.0% 
Total Count 25 75 100 
% within HER - 2 100.0% 100.0% 100.0%
P value : 0.312 ( > 0.05) 
 Among the cases showing HER-2/Neu over expression, 76% were from 
pyloroantral region, 4% were from cardiac region,16%  from body and 4% of 
cases with fundus involvementshowed HER-2/Neu over expression. 
Association of site of tumour withHER-2/Neu over expression was not 
statistically significant. (Table12&Chart 12). 
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Table 13: Association of type of specimen with HER-2/Neu Expression 
  
HER - 2 
Total Positive Negative 
TYPE Endoscopic 
biopsies 
Count 20 53 73 
  % within HER - 
2 
80.0% 70.7% 73.0% 
Gastrectomy Count 5 22 27 
  % within HER - 
2 
20.0% 29.3% 27.0% 
Total Count 25 75 100 
% within HER - 
2 
100.0% 100.0% 100.0%
 
P value : 0.363 ( > 0.05) 
 Among Her -2 positive cases, 80% are from endoscopic biopsies and 
20% from gastrectomy specimen. Association of type of specimen withHER-
2/Neu over expression was not statistically significant. (Table13 &Chart 13) 
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Table 14: Association of  clinical features with HER-2/Neu 
  
HER - 2 
Total Positive Negative 
CLINICAL 
FEATURE 
Abdominal 
pain 
Count 8 21 29 
% within HER - 2 32.0% 28.0% 29.0% 
Abdominal 
Pain & 
Obstruction 
Count 2 19 21 
% within HER - 2 8.0% 25.3% 21.0% 
All the 
three 
Count 4 7 11 
% within HER - 2 16.0% 9.3% 11.0% 
Abdominal 
Pain & 
Loss of 
Weight 
&Apetite 
Count 6 16 22 
% within HER - 2 24.0% 21.3% 22.0% 
Obstruction Count 2 5 7 
% within HER - 2 8.0% 6.7% 7.0% 
Obstruction 
& Loss of 
Weight 
&Apetite 
Count 1 4 5 
% within HER - 2 4.0% 5.3% 5.0% 
Loss of 
Weight 
&Apetite 
Count 2 3 5 
% within HER - 2 8.0% 4.0% 5.0% 
Total Count 25 75 100 
% within HER - 2 100.0% 100.0% 100.0% 
 
    P value : 0.634 ( > 0.05)   
  Among Her – 2 positive cases most common symptom is  only 
abdominal pain (32%) and least common is combination of obstruction and loss 
of weight(4%). No statistical significant between two groups 
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Table 14: Association of Endoscopic Appearance with HER-
2/NeuExpression 
  
HER - 2 
Total Positive Negative 
ENDOSCOPY Ulcer Count 20 53 73 
  % within HER 
- 2 
80.0% 70.7% 73.0% 
Growth Count 5 22 27 
  % within HER 
- 2 
20.0% 29.3% 27.0% 
Total Count 25 75 100 
% within HER 
- 2 
100.0% 100.0% 100.0% 
P Value: 0.363  
 Among Her – 2 positive cases ,ulcer in endoscopy accounts 80% and 
growth appearance in endoscopy accounts 20%. No statistical significant 
between two groups 
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Table 15: Association of Gross Appearance with HER-2/Neu 
  
HER - 2 
Total Positive Negative 
GROSS Ulcerative Count 12 33 45 
  % within 
HER - 2 
48.0% 44.0% 45.0% 
Proliferative Count 13 37 50 
  % within 
HER - 2 
52.0% 49.3% 50.0% 
Polypoidal Count 0 2 2 
  % within 
HER - 2 
0.0% 2.7% 2.0% 
Infiltrative Count 0 3 3 
  % within 
HER - 2 
0.0% 4.0% 3.0% 
Total Count 25 75 100 
% within 
HER - 2 
100.0% 100.0% 100.0% 
 
P value: 0.624 (>0.05%) 
Among the cases showing HER-2/Neu over expression, 48% were ulcerative 
type, 52% were proliferative type and none were  polypoidal and infiltrative 
type. No statistically significant associationwas found between gross 
appearance and HER-2/Neu over expression.(Table15 & Chart 15) 
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Table 16: Association of Tumour Grade with HER-2/Neu Expression 
HER - 2 
Total Positive Negative 
HPE Well  
differentiated 
Count 7 10 17 
  % within HER 
- 2 
28.0% 13.3% 17.0% 
Moderately 
differentiated 
Count 13 29 42 
  % within HER 
- 2 
52.0% 38.7% 42.0% 
Poorly 
differentiated 
Count 5 36 41 
  % within HER 
- 2 
20.0% 48.0% 41.0% 
Total Count 25 75 100 
% within HER 
- 2 
100.0% 100.0% 100.0% 
 
P value: 0.034 ( <0.05) 
Positivity for HER-2/Neu was seem to be more with moderately  
differentiated cases (52%) than well differentiated (28%) or poorly 
differentiated (20%) cases and the association was statistically 
significant. (P value < 0.05) (Table 16 & Chart 16) 
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DISCUSSION 
 Gastric cancer had been described as early   as 1500 BC in manuscripts 
from ancient Egypt called Ebers Papyrus(1) . Gastric cancer is the fourth most 
common cancer and the second leading cause of  death due to cancer worldwide  
after lung cancer(2).  
 Gastric cancer is more common in male than in female in the ratio of 2:1. 
It is a disease of elderly  with higher incidence around 65yrs.  For last few years 
there is decline in incidence rate  in the western countries (8). In Asia it is still 
one ofthe most common malignancies accounting for 18% of all 
malignancies.In countries like Japan and Korea it accounts for 56% of 
malignancies (7). 
 The  poor prognosis of  gastric adenocarcinoma is due to its late 
presentation, nonspecific symptoms like dyspepsia in early stage and limitations 
in treatment options. Molecular markers are vital in determining the disease 
progression and hence disease outcome, survival  and prognosis. An association 
between clinicopathological  features and molecular markers of gastric adeno 
carcinoma would give a clue toward the relationship between them and hence 
provide us an extra tool to combat the high mortality due to these carcinomas. 
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 Though many studies  have been conducted in gastric carcinoma all over 
the world  for the expression of  HER-2/Neu and their prognostic significance, 
the results are still contradictory. Some found a statistically significant 
association of these markers with prognosis and survival, while others found no 
such association. 
 In this study, immunohistochemical evaluation was done in 100gastric 
carcinoma cases; attempt was made to correlate the expressionof HER-2/Neu 
with various clinicopathological factors . 
 The age of the patients ranged from 27 years to 72 years, with a mean age 
of 60.3years. The age group showing the greatest incidence of gastric carcinoma 
was 55 to  65 years. This is correlated with Zhang HK et al , who observed a 
mean age of 52 years with the age group ranging between 25 and 75 years. 
 In the current study, the incidence of gastric carcinoma in males  were 
68%  and  females were 28% . Nobuyuki Igarashi et al  who noted an incidence 
of 74.1% and 25.9% in males and females respectively has been correlated with 
our study. 
 The most common site of gastric carcinoma in this study was 
pyloroantral region (60%), which is similar to the study by C Fondevilla et al  
showing occurrence of 51%of cases in the pyloroantral region(44). 
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   In this study moderately differentiated tumours  were morecommon than 
other grades accounting for 42% of cases, which is correlated with  Fondevila et 
al study (49%)(44%). 
The most common clinical feature  in this study is abdominal pain only (29%) 
which is correlated with Wanebo HJ et al showing 30 % of cases with 
abdominal pain only. 
                   The most common gross appearance seen in our study population is 
proliferative pattern (50%) and least one is polypoidal with incidence of 2% 
Her -2 Overexpression is seen in 25% of cases correlated with 
Tanner et al who  got 36.6% results and  Yano et al study in which 27 % of 
cases were positive for Her -2 receptor(51) 
Correlation of HER-2/Neu Expression with Various 
Clinicopathological  Factors 
 H R Raziee et al (2007)(15) studied 100 cases of gastric tumours & found a 
significant association of HER-2/Neu over expression with  well differentiated 
grade, and no association between age, gender, location of tumour and depth of 
infiltration. 
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Zhiyong Liam et al (2008) studied 100 cases and found no significant 
association of over expression of HER-2/Neu withany clinicopathological 
factors. 
 Similarly ,S. D. Xie et al (2009)(60)  and  Xie Li Zhang et al (2009)  were 
not able to demonstrate association with any other known clinicopathological 
and prognostic factors. 
 In this study, a statistically significant association was obtained between 
histological grade and HER-2/Neu overexpression. 
 Positivity for HER-2/Neu was seem to be more with moderately 
differentiated cases (52%) than well differentiated (28%) or poorlydifferentiated 
(20%) cases with P value < 0.05. This is correlated with Razee et al(15) , who 
found that Her -2 over expression in noted in Moderately differentiated (67%) 
and well differentiated tumours (20%).  
All other variables compared  like age, sex, clinical features,  location of tumour 
, gross and endoscopic appearance were found to be statistically non significant. 
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SUMMARY 
 Gastric carcinoma had a peak incidence in the 55 to 65 years agegroup. 
The oldest age of presentation was 80 years and theyoungest age of 
presentation was 27 years. 
 Incidence was more in males (68%) than females (32%). 
 Among the 100 cases 27were gastrectomy specimens and73 were 
endoscopic biopsies. 
 The most common site of occurrence was pyloroantral region(60%). 
 Proliferative type was the most common morphological type seen with 
incidence of 50% 
 Moderately  differentiated histological grade was the most common 
grade constituting for 42% of gastric carcinoma cases. 
 The most common clinical feature is abdominal pain only accounting 
29% of cases. 
 HER-2/Neu over expression was seen in 25% of cases. 
 A significant association was found between HER-2/Neu over          
expression and histologic grading of gastric adenocarcinoma. 
 No association was found between HER-2/Neu expression and 
age,sex,site of tumour, gross appearance, endoscopic appearance and 
clinical features 
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CONCLUSION 
 Many  gastric adeno carcinoma patients in Government Kilpauk Medical 
College Hospital  were older than 5o years of age with male preponderance 
which is similar to several other studies conducted throughout the world. 
 The most common Clinical feature is abdominal pain and the common 
site involved being Pyloroantral region. Morphlogic subtype among them is 
done and proliferative type is found to be the most common. The most common 
histologic grade is moderate differentiation. 25% of gastric adenocarcinoma 
cases showed Her-2 receptor over expression. Statistical significance was found 
out between Her -2 receptor over expression and histological grade. 
 Delays in diagnosis and limitation of therapeutic options contribute to  
poor prognosis of gastric adeno carcinoma. Hence, the contribution of these 
genetic markers like Her -2 receptor  towards prediction of progression and 
prognosis along with newer therapeutic modalities could be of immense benefit 
in gastric cancer patients. 
                                                     ANNEXURE – I 
 
                                                      PROFORMA 
Case number :                                                                        Name : 
HPE number :                                                                        Age : 
IP number :                                                                            Sex : 
Clinical features : 
Clinical diagnosis : 
Endoscopy : 
Previous HPE report: 
Nature of specimen : Total gastrectomy/Subtotal gastrectomy/Endoscopic 
biopsy 
Gross appearance: 
Tumour site : 
MICROSCOPY: 
 
Histological grade : G1 / G2 / G3 
IMMUNOHISTOCHEMISTRY 
HER-2/Neu: Intensity &Percentage of cells showing staining 
 
 
  
ANNEXURE II 
 
TNM STAGING OF GASTRIC TUMOURS 
 
T – Primary Tumour 
TX - Primary tumour cannot be assessed 
T0 - No evidence of primary tumour 
Tis - Carcinoma in situ 
T1 - Tumour invades lamina propria or submucosa 
 - T1a-Tumour invades lamina propria or muscularis mucosa 
 - T1b- Tumour invades submucosa 
T2 - Tumour invades muscularispropria 
T3 - Tumour penetrates subserosa without invasion of serosa 
T4 - Tumour invades serosa or adjacent structures 
 - T4a- Tumour invades serosa 
 - T4b- Tumour invades adjacent structures 
N – Regional Lymph Nodes 
NX - Regional lymph nodes cannot be assessed 
N0 - No regional lymph node metastasis 
N1 - Metastasis in 1 to 2 regional lymph nodes 
N2 - Metastasis in 3 to 6 regional lymph nodes 
N3 - Metastasis in more than 7 regional lymph nodes 
 
M – Distant Metastasis 
MX - Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
STAGE GROUPING 
Stage 0 Tis N0 M0 
 
Stage IA T1 N0 M0 
 
Stage IB T1 N1 M0 
T2 N0 M0 
 
Stage IIAT1 N2 M0 
T2 N1 M0 
T3 N0 M0 
 
Stage IIB T1 N3 M0 
T2 N2 M0 
T3 N1 M0 
 
Stage IIIA T2 N3 M0 
T3 N2 M0 
T4a N1 M0 
 
Stage IIIB T2 N3 M0 
T3 N2 M0 
T4a N1 M0 
 
Stage IIICT4a N2 M0 
T4b N0 M0 
T4b N1 M0 
 
Stage IV Any T Any N M1 
  
ANNEXURE III 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1.  4μ thick sections were cut from formalin fixed paraffin 
embeddedtissue samples and transferred to gelatin-chrome alum 
coated slides. 
2.  The slides were incubated at 58ºC for overnight. 
3.  The sections were deparaffinized in xylene for 15 minutes x 2 
changes. 
4.  The sections were dehydrated with absolute alcohol for 5 minutes x 
2changes. 
5.  The sections were washed in tap water for 10 minutes. 
6.  The slides were then immersed in distilled water for 5 minutes. 
7.  Heat induced antigen retrieval was done with microwave oven 
inappropriate temperature with citrate buffer for 20 to 25 minutes. 
8.  The slides were then cooled to room temperature and washed 
inrunning tap water for 5 minutes. 
9.  The slides were then rinsed in distilled water for 5 minutes. 
10.  Wash with appropriate wash buffer (phosphate buffer) for 5 
minutes x2 changes. 
11.  Apply peroxidase block over the sections for 10 minutes. 
12.  Wash the slides in phosphate buffer for 5 minutes x 2 changes. 
13.  Cover the sections with power block for 15 minutes. 
14.  The sections were drained (without washing) and appropriate 
primaryantibody was applied over the sections and incubated for 1 
hour. 
15.  The slides were washed in phosphate buffer for 5 minutes x 
2changes. 
16.  The slides were covered with Super Enhancer for 30 minutes. 
17.  The slides were washed in phosphate buffer for 5 minutes x 
2changes. 
18.  The slides were covered with SS Label for 30 minutes. 
19.  Wash in phosphate buffer for 5 minutes x 2 changes. 
20.  DAB substrate was prepared by diluting 1 drop of DAB 
chromogen to1 ml of DAB buffer. 
21.  DAB substrate solution was applied on the sections for 8 minutes. 
22.  Wash with phosphate buffer solution for 5 minutes x 2 changes. 
23.  The slides were washed well in running tap water for 5 minutes. 
24.  The sections were counterstained with Hematoxylin stain for 
2seconds (1 dip). 
25.  The slides were washed in running tap water for 3 minutes. 
26.  The slides are air dried, cleared with xylene and mounted with 
DPX. 
 
  
ANNEXURE IV 
 
 
SCORING SYSTEM FOR THE IMMUNOHISTOCHEMICAL 
MARKER HER-2 RECEPTOR 
0  : no discernible staining or background type staining; 
1+  :  discontinuous membrane staining; 
2+  :  membrane staining with moderate intensity 
3+  :  strong and complete plasma membrane staining. 
More than 10% of the cells are required to meet the criteria for HER2 
analysis. 3+ cases are classified as over expression 
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MALE‐1 ENDOSCPOIC BIOPSY  ‐1  CADRIA‐1 ABDOMINAL PAIN‐1 ULCER‐1 ULCERATIVE ‐1 GRADE1 ‐1 POSITIVE1
FEMALE‐0 GASTRECTOMY‐2 BODY‐2 OBSTRUCTION‐2 GROWTH‐2 PROLIFERATIVE‐2 GRADE2 ‐2 NEAGATIVE‐2
FUNDUS‐3 LOSS W & A‐3 POLYPOIDAL‐3 GRADE3‐3
PYLORO ANTRUM‐4 INFILTRATIVE‐4
S.NO BIOPSY NO AGE GENDER TYPE SITE CLINICAL FEATURE ENDOSCOPY GROSS HPE HER ‐2
1 2318/14 65 1 2 4 1,2,3 1 1 2 1
2 2321/14 54 1 2 4 1,2,3 1 2 1 1
3 2333/14 35 1 1 3 1 2 2 3 2
4 2338/14 52 2 2 1 1,2 1 1 3 2
5 2369/14 59 1 1 2 1 1 1 1 2
6 2422/14 59 1 1 4 1,2.3 1 3 2 2
7 2442/14 58 1 1 4 1,2,3 1 1 3 2
8 2523/14 27 2 2 4 1,2 2 2 2 2
9 2526/14 56 1 1 2 2 1 1 3 2
10 2535/14 51 1 1 4 1,2 1 1 2 2
11 2539/14 46 1 1 4 1,2,3 1 4 2 2
12 2739/14 51 2 1 1 1 1 2 2 2
13 2882/14 50 1 1 3 1,2 1 4 3 2
14 2913/14 59 2 1 4 1,2 1 1 2 1
15 2928/14 58 1 1 4 1 1 1 1 1
16 23/15 61 2 1 4 1 1 1 2 1
17 31/15 54 1 1 4 1 1 1 1 1
18 40/15 40 2 1 4 1 1 1 2 1
19 70/15 55 1 1 4 1,3  1 1 3 2
20 95/15 69 2 2 2 1,3 2 2 2 2
21 102/15 66 2 2 2 1 1 2 3 2
22 120/15 63 1 2 4 1,2 1 1 3 2
23 188/15 59 1 2 3 1,2,3 1 2 2 2
24 397/15 50 1 1 4 1,3 1 1 1 2
25 502/15 29 1 1 1 1 1 2 2 2
26 557/15 51 2 2 4 1,2,3 1 1 2 2
27 574/15 62 1 1 4 1,2 2 2 2 2
28 588/15 54 1 1 3 1 1 2 1 2
29 708/15 53 1 1 4 1,2,3 1 2 2 2
30 797/15 39 1 1 2 1 1 2 1 1
31 816/15 52 1 1 2 2 1 2 2 2
32 822/15 51 1 1 2 1,2 1 1 3 2
33 850/15 50 2 2 4 1,2 2 1 3 2
34 922/15 59 2 1 4 3 1 2 2 1
35 929/15 67 1 1 4 1,2 2 2 3 2
36 1141/15 41 1 1 4 1 2 2 2 1
37 1192/15 61 1 1 4 1 1 1 1 1
38 1194/15 62 1 1 4 2 1 1 2 2
39 1286/15 58 1 1 4 2 2 2 1 1
40 1290/15 59 2 2 4 2,3 1 2 2 1
41 1359/15 42 1 1 2 1 1 1 1 2
42 1366/15 52 1 1 4 3 1 2 2 1
43 1469/15 57 1 1 2 2,3 1 1 3 2
44 1560/15 58 1 1 4 1,3 2 2 2 2
45 1649/15 67 2 1 4 1,3 2 2 2 2
46 1847/15 37 1 1 4 1,3 2 2 2 2
47 1881/15 58 1 1 2 3 1 1 2 2
48 1924/15 36 1 1 4 1,2 2 1 3 2
49 1925/15 46 1 2 4 1 1 2 2 2
50 1995/15 49 2 1 2 1,3 1 4 3 2
51 1997/15 72 1 2 4 1 1 2 1 2
52 2015/15 61 1 1 4 1,2 1 1 3 2
53 2050/15 68 1 1 4 1,2 1 2 2 1
54 2068/15 35 1 1 2 1,2 1 2 3 2
55 2122/15 67 2 2 2 2 1 1 3 2
56 2139/15 64 2 2 4 1,3 1 2 3 2
57 2192/15 59 1 2 4 1,3 1 2 3 2
58 2279/15 58 1 1 4 1,3 1 2 3 2
59 2397/15 57 1 1 2 1 1 1 3 2
60 2399/15 38 2 1 3 1,2,3 2 2 3 1
61 2413/15 71 1 2 4 1 1 2 3 2
62 2640/15 63 2 1 4 1 1 2 2 2
63 2648/15 56 1 2 4 1,3 2 2 3 1
64 2732/15 57 1 1 2 2,3 2 1 2 2
65 2774/15 57 1 1 4 2 2 2 2 2
66 2784/15 27 1 2 2 1 2 2 3 2
67 008/16 73 1 1 2 1 1 1 3 2
68 27/16 69 2 1 2 1 1 2 3 2
69 37/16 58 1 1 4 1,2 1 1 2 2
70 75/16 80 2 1 1 1,3 1 1 2 2
71 82/16 67 1 1 4 1,2 2 2 3 2
72 92/16 39 1 1 4 1,2 1 1 3 2
73 104/16 63 1 1 4 1 2 2 1 2
74 112/16 61 1 2 4 2,3 2 2 2 2
75 114/16 55 2 2 2 2,3 1 1 3 2
76 155/16 40 2 1 4 1,3 1 1 2 1
77 178/16 50 1 1 2 1,3 1 1 3 1
78 216/16 34 1 1 4 1 1 1 1 2
79 250/16 59 2 1 4 1,2,3 2 3 1 2
80 265/16 54 1 1 4 1,2 1 2 2 2
81 288/16 56 1 1 1 1 2 1 2 2
82 293/16 55 2 1 2 1 1 2 2 2
83 324/16 37 1 1 2 3 2 1 3 2
84 353/16 52 1 1 2 1 1 2 1 1
85 384/16 49 1 1 4 1,3 1 1 3 1
86 394/16 57 2 1 2 1,3 1 1 1 2
87 402/16 45 1 1 4 1,3 1 1 2 2
88 409/16 63 2 2 4 1,3 2 1 2 2
89 410/16 62 1 2 4 1,3 1 2 3 2
90 419/16 61 1 1 1 1,2,3 1 1 2 1
91 433/16 60 2 1 2 1,3 1 1 1 2
92 440/16 57 2 1 2 1,3 2 2 3 1
93 446/16 42 1 2 3 1,2 2 2 3 2
94 474/16 59 1 2 3 1,2 1 2 3 2
95 485/16 56 1 1 4 1 1 1 3 2
96 511/16 70 2 2 2 1 1 2 3 2
97 540/16 72 2 1 4 1,3 1 2 2 1
98 595/16 61 2 2 4 2 1 1 2 1
99 613/16 42 2 1 4 3 1 2 3 2
100 902/16 54 1 1 4 1,2 2 2 3 2
101
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